Patel Naimish
Chief Medical Officer
Patel Naimish has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Jun 1, 2026.
On the most recent filing, Patel Naimish is listed as Chief Medical Officer at CRISPR Therapeutics AG. Inside the rolling window, Patel Naimish reported 1 open-market purchase totaling $50K in CRSP and 2 open-market sales totaling $363K in CRSP. The largest disclosed transaction in the window is a sale of 3,786 CRSP shares on May 29, 2026, worth $211K.
Companies traded
Other insiders at CRSP
Insider Buying
$50K
reported purchases (SEC code P)
Insider Selling
$363K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Patel Naimish made?
Patel Naimish has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Patel Naimish trade?
Patel Naimish has filed SEC Form 4 disclosures for 1 company, including CRSP.
When was Patel Naimish's most recent SEC Form 4 filing?
Patel Naimish's most recent SEC Form 4 filing on Tracefour is dated Jun 1, 2026.
What is Patel Naimish's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Patel Naimish is listed as Chief Medical Officer.
What is Patel Naimish's total buy and sell value in the current window?
Inside the rolling retention window, Patel Naimish bought $50K and sold $363K based on SEC Form 4 filings.
What was Patel Naimish's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,786 CRSP shares on 2026-05-29, worth $211K, per SEC Form 4 filings.